Platform Trial in Stage 1 Diabetes: Comparing Golimumab vs Placebo

NHS rolls out teplizumab immunotherapy to delay type 1 diabetes onset by three years

The NHS is rolling out teplizumab, an immunotherapy drug that delays the onset of type 1 diabetes by an average of three years in children a

Health tech companies rush to market 'GLP-1 ready' products as weight loss drug trend grows

This article from Verge's Optimizer newsletter examines how health tech companies are marketing products specifically to GLP-1 drug users (p

National Psoriasis Foundation Review Examines GLP-1 Receptor Agonists for Psoriasis with Metabolic Comorbidities

This review from the US National Psoriasis Foundation Medical Board provides an evidence-informed narrative synthesis on GLP-1 receptor agon

Study: GLP-1 drugs like semaglutide linked to lower amputation risk in diabetes patients with peripheral artery disease

A new study suggests that GLP-1 receptor agonists (like Ozempic and Wegovy) are associated with better outcomes in people with type 2 diabet

GSK initiates phase III programme for novel type 2 diabetes medication, Syncria® (albiglutide)

Real-World EV Plus Pembro Success Seen in Urothelial Cancer